硼替佐米与泼尼松龙和霉酚酸酯联合治疗对 NZB/WF1 小鼠肾炎疗效的比较。

Comparison of therapeutic efficacy between bortezomib and combination treatment of prednisolone and mycophenolate mofetil on nephritis in NZB/WF1 mice.

机构信息

Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.

出版信息

Clin Exp Rheumatol. 2010 May-Jun;28(3):393-6. Epub 2010 Jun 23.

PMID:20497633

Abstract

OBJECTIVES

We investigated the efficacy of bortezomib on nephritis in NZB/WF1 mice, and compared it to prednisolone (PL) and mycophenolate mofetil (MMF) treatment.

METHODS

Twenty-three NZB/WF1 mice were divided into four groups (untreated, 0.1 mg/kg and 1 mg/kg bortezomib-treated, and PL plus MMF-treated). Proteinuria, glomerular IgG deposition, cellular proliferation and histologic damages were evaluated.

RESULTS

In comparison with the untreated mice, 1 mg/kg bortezomib significantly reduced proteinuria and attenuated glomerular IgG deposition, cellular proliferation and histologic damages similar to PL plus MMF. 0.1 mg/kg bortezomib significantly improved glomerular IgG deposition and histologic damages except proteinuria or cellular proliferation compared to untreated mice. PL plus MMF showed significantly greater inhibition of cellular proliferation and histologic damage than 1 mg/kg bortezomib.

CONCLUSIONS

We found that 1 mg/kg bortezomib significantly improved lupus nephritis in NZB/WF1 mice. However, its efficacy did not exceed PL plus MMF treatment.

摘要

目的

我们研究硼替佐米治疗 NZB/WF1 小鼠肾炎的疗效，并与泼尼松龙（PL）和霉酚酸酯（MMF）治疗进行比较。

方法

将 23 只 NZB/WF1 小鼠分为四组（未治疗组、0.1mg/kg 和 1mg/kg 硼替佐米治疗组、PL 加 MMF 治疗组）。评估蛋白尿、肾小球 IgG 沉积、细胞增殖和组织学损伤。

结果

与未治疗组相比，1mg/kg 硼替佐米显著减少蛋白尿，减轻肾小球 IgG 沉积、细胞增殖和组织学损伤，与 PL 加 MMF 相似。与未治疗组相比，0.1mg/kg 硼替佐米显著改善肾小球 IgG 沉积和组织学损伤，但不改善蛋白尿或细胞增殖。PL 加 MMF 显示出比 1mg/kg 硼替佐米更显著的抑制细胞增殖和组织学损伤的作用。